Commenting on Friday’s speech (16 November) by George Osborne, Chancellor of the Exchequer at the Royal Society, Stephen Whitehead, Chief Executive of the ABPI, said: “I am pleased to hear the Government’s continued commitment to Life Sciences in the UK which is being backed with real investment."
“I am pleased to hear the Government’s continued commitment to Life Sciences in the UK which is being backed with real investment. The Chancellor marked out a number of areas in which the UK is aiming to be a world leader and so I am delighted that synthetic biology and regenerative medicine were highlighted. Both of these fields of science will be of huge importance to developing the next generation of medicines in battling disease and treating patients. The pharmaceutical industry in partnership with Government will be at the forefront driving forward these advances. The challenge will then be ensuring that ground-breaking treatments, once ready for use, actually find their way to patients.”
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: firstname.lastname@example.org
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.